Welcome to our dedicated page for Dermata Therapeutics SEC filings (Ticker: DRMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dermata Therapeutics, Inc. (DRMA) SEC filings page on Stock Titan aggregates the company’s official U.S. regulatory disclosures, offering a structured view of how this dermatology-focused biotechnology issuer reports its activities. Dermata uses SEC filings to describe progress with its Spongilla technology platform, clinical programs such as XYNGARI™ and DMT410, financing arrangements, and key corporate decisions.
Current and prospective investors can review Form 8-K filings for material events, including press release disclosures about clinical trial data, strategic pivots, financing transactions, and significant agreements. For example, Dermata has filed 8-Ks discussing its corporate updates and financial results, the presentation of Phase 3 STAR-1 acne data, increases to its at-the-market offering capacity, and the termination of a License Agreement with Villani, Inc. related to sponge-based pharmaceutical products.
Annual Form 10-K and quarterly Form 10-Q reports (when available) provide more comprehensive information on Dermata’s business, risk factors, financial statements, and details on its lead programs XYNGARI™ and DMT410. These filings also reference key licensing arrangements, intellectual property, and the company’s shift toward over-the-counter pharmaceutical dermatology products.
On Stock Titan, Dermata’s filings are complemented by AI-powered summaries designed to clarify complex sections of lengthy documents, such as clinical trial descriptions, capital structure changes, and agreement terms. Users can quickly understand the implications of new 8-Ks, 10-Qs, and 10-Ks without reading every page, while still having direct access to the full text filed with the SEC. This page also surfaces information relevant to equity offerings and at-the-market programs, helping readers follow how Dermata funds its dermatology pipeline and OTC initiatives.
Dermata Therapeutics, Inc. is asking stockholders to approve seven proposals at its virtual 2026 annual meeting on May 27, 2026. The agenda includes electing three Class II directors to serve until 2029 and ratifying CBIZ CPAs P.C. as independent auditor for the year ending December 31, 2026.
Stockholders are also asked to approve, for Nasdaq Listing Rule 5635(d) purposes, the issuance of common shares underlying warrants that could equal or exceed 20% of common stock outstanding before issuance, the repricing of warrants exercisable for up to 120,734 shares, and an increase in the 2021 Omnibus Equity Incentive Plan reserve to 402,214 shares. An adjournment proposal would allow more time to solicit votes if needed.
Only holders of record on March 30, 2026, when 4,022,143 shares of common stock were outstanding, may vote. The meeting will be held exclusively online, and the Board recommends voting FOR all director nominees and FOR Proposals 2 through 6.
Dermata Therapeutics (DRMA) is soliciting proxies for its virtual 2026 Annual Meeting on May 27, 2026 to vote on director elections and several governance and capital-structure proposals. The meeting notice lists seven proposals including: election of three Class II directors; ratification of CBIZ as auditor; approval to issue shares underlying warrants in an amount equal to or in excess of 20% of outstanding Common Stock; repricing of warrants exercisable for 120,734 shares; and an increase of the 2021 Plan reserve to 402,214 shares. Shares outstanding were 4,022,143 as of the record date, March 30, 2026. The Board recommends a vote FOR all listed proposals. The meeting will be virtual and stockholders must register to attend and vote.
Dermata Therapeutics, Inc. files its annual report describing a major strategic shift from prescription dermatology to over-the-counter and cosmetic skincare under its new Tome brand. After achieving statistically significant Phase 3 results in 2025 for its acne candidate XYNGARI, the company chose not to pursue the traditional prescription path and instead focus on faster-to-market consumer products.
Dermata plans to commercialize once-weekly Tome Foundational Treatment and a Clearing Treatment acne system built around its proprietary Bioneedle technology, derived from the freshwater sponge Spongilla lacustris. The products are intended to offer skin renewal and acne control with simplified routines and natural ingredients.
The company outlines a dual go-to-market strategy combining direct-to-consumer e-commerce with a professional B2B channel, including a Tome certification program for aestheticians and dermatology practices. It also highlights potential future applications of Bioneedle for broader skin conditions and a paused collaboration using the platform for topical delivery of botulinum toxin.
Dermata Therapeutics reported 2025 results and detailed a strategic pivot from prescription dermatology to direct-to-consumer skincare under its new Tome brand. The first Tome product, a once-weekly Foundational Treatment mask, is planned for launch in the middle of 2026, with a Clearing Treatment for acne expected to follow.
For 2025, Dermata posted a net loss of $7.6 million, improving from a $12.3 million net loss in 2024, as research and development expenses declined to $2.9 million from $8.2 million, largely after completing its STAR-1 acne study. Selling, general and administrative expenses rose to $4.8 million from $4.3 million, mainly due to increased marketing.
Cash and cash equivalents were $7.5 million as of December 31, 2025, up from $3.2 million a year earlier, driven by approximately $12.1 million of net financing proceeds and $7.8 million of cash used in operations. Dermata raised $15.4 million in gross proceeds during 2025 and early 2026 and expects its cash to fund operations into the first quarter of 2027 while it prepares multiple Tome products for market.
Dermata Therapeutics, Inc. senior vice president of regulatory affairs Maria E. Bedoya-Toro Munera bought 1,000 shares of common stock in an open-market transaction at $1.27 per share on February 17, 2026. Following this purchase, she holds 1,012 shares directly and 34 shares indirectly through the Munera Family Trust.
Dermata Therapeutics, Inc. reported that director Mary Fisher has notified the company she will resign from its Board of Directors, including all committee roles, effective March 31, 2026. The filing states her decision is tied to her employer’s recent acquisition, which will no longer permit her to serve on Dermata’s board.
The company notes that her resignation is not due to any disagreement with Dermata or its management regarding operations, policies, or practices. Once her resignation becomes effective, the size of the Board will be reduced from eight to seven members.
Dermata Therapeutics, Inc. investor update: Gerald T. Proehl filed Amendment No. 10 to his beneficial ownership report, stating that he may be deemed to beneficially own 694,687 shares of Dermata common stock. This represents 17.3% of the company’s outstanding common stock as of a recent share count.
The filing explains that his holdings include shares and options held directly, shares and warrants held through Proehl Investment Ventures LLC, and shares held by certain trusts for which he serves as trustee. The amendment also notes that there have been no purchases or sales of Dermata common stock or related convertible securities by him or entities he controls since a prior amendment earlier in 2026.
Dermata Therapeutics filing: Armistice Capital and Steven Boyd report shared beneficial ownership of 53,910 shares, representing 4.99% of common stock. The report, filed as a joint Schedule 13G/A, states Armistice Capital is investment manager to Armistice Capital Master Fund Ltd., which directly holds the shares, and that voting and dispositive power over the shares is exercised pursuant to an Investment Management Agreement. The Master Fund is identified as the direct holder and the filing notes the Master Fund "specifically disclaims beneficial ownership" due to its inability to vote or dispose of the securities under that agreement.
Dermata Therapeutics — Armistice Capital, LLC and Steven Boyd filed an amendment reporting beneficial ownership of 53,910 shares, representing 4.99% of the company's common stock. The filing states the reported percentage is based on information from the issuer and lists shared voting and dispositive power over those shares.
The filing explains Armistice Capital is investment manager to Armistice Capital Master Fund Ltd., the direct holder of the shares, and that Mr. Boyd, as managing member, may be deemed to beneficially own the securities. The Master Fund disclaims beneficial ownership due to the Investment Management Agreement. The joint filing is signed by Steven Boyd on 02/17/2026.